Last reviewed · How we verify
NCT06276738
The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease
trial testing LINFU® (Low Intensity Non-Focused Ultrasound excitation of the pancreas) in Pancreatic Cancer in 1,000 participants. Not yet recruiting.
1 March 2034
Quick facts
| Lead sponsor | Adenocyte, LLC |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 30 June 2024 |
| Primary completion | 1 March 2034 |
| Estimated completion | 1 May 2034 |
Drugs / interventions tested
- LINFU® (Low Intensity Non-Focused Ultrasound excitation of the pancreas)
Conditions studied
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Jaundice — all drugs for Jaundice →
- Abdominal Neoplasm — all drugs for Abdominal Neoplasm →
Sponsor
Adenocyte, LLC
Who can join
Adults 18 to 90, any sex, with Pancreatic Cancer or Jaundice. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluate LINFU® in patients who exhibit signs or symptoms (i.e. jaundice, abdominal pain, weight loss, nausea and vomiting etc.) suggestive of pancreatic cancer (PDAC) or have evidence of imaging studies suggestive of PDAC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06276738
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Other Adenocyte, LLC trials
Trials by the same sponsor.
- NCT06276764 — The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas) · enrolling by invitation
- NCT06276803 — The LINFU® U.S. Registry for the in the General Population Without Risk Factors · not yet recruiting
- NCT06157671 — The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma · enrolling by invitation
- NCT04793633 — Evaluating LINFU™: A Noninvasive Method for Collecting Pancreatic Cells for the Early Detection of Pancreatic Cancer · enrolling by invitation
- NCT05161013 — A Proof-of-Concept Study Evaluating LINFU™ · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06276738 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Adenocyte, LLC
- Last refreshed: 14 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06276738.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing